A petition that required routine vaccination for older children reached more than 815,000 signatures subsequent the widely-publicized death of two year old Faye Burdett last year.
The Joint Committee on Vaccination and Immunization (JCVI) said there is inadequate supply to offer it to children in this younger age group without jeopardizing stocks for the in progress immunization program.
But while granting that the Men B vaccine could establish cost effective for children aged between 13 and 24 months.
The Meningitis Research Foundation argues that the possibility of the virus posed to children aged 13 to 24 months is only to some extent less than that for the standard vaccination age (under one year), and that a positive proposal to develop its use.
According to MRF chief executive Vinny Smith “Vaccinating children under two years old against Men B meningitis and septicemia would have made a major, life-saving divergence to susceptible members of our families. This is a major prospect missed to save young lives from this alarming disease this winter”.
According to chief executive Liz Brown, `”We will continue to fight against a system that distinguishes against the health of the nation’s children on an ability to pay basis”.
Both charities are also calling for a national valuation to demonstrate if the vaccine can prevent teenagers carrying the infection, as called for by the JCVI more than two years ago, beside an improvement of the cost effectiveness framework forming the foundation of verdict on vaccines to safe a more level playing field.
Date: 14th July 2016
http://www.pharmatimes.com/news/uk_officials_reject_calls_to_expand_men_b_vaccination_1071211